Get the Stockscreener App
1.30
0.00%
0.00
After Hours:
1.31
0.01
+0.77%
Pliant Therapeutics Inc stock is traded at $1.30, with a volume of 1.25M.
It is up +0.00% in the last 24 hours and up +7.44% over the past month.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.
See More
Previous Close:
$1.30
Open:
$1.28
24h Volume:
1.25M
Relative Volume:
1.02
Market Cap:
$79.88M
Revenue:
$5.03M
Net Income/Loss:
$-185.41M
P/E Ratio:
-0.4207
EPS:
-3.09
Net Cash Flow:
$-139.79M
1W Performance:
+0.78%
1M Performance:
+7.44%
6M Performance:
-17.72%
1Y Performance:
-88.33%
1-Day Range:
$1.28
$1.36
1-Week Range:
$1.24
$1.36
52-Week Range:
$1.1001
$12.88
Pliant Therapeutics Inc Stock (PLRX) Company Profile
Name
Pliant Therapeutics Inc
Sector
Industry
Phone
650-481-6770
Address
331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA
Compare PLRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PLRX
Pliant Therapeutics Inc
|
1.30 | 79.88M | 5.03M | -185.41M | -139.79M | -3.09 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.41 | 118.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
753.55 | 79.40B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
814.74 | 51.18B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
357.98 | 48.88B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
339.32 | 37.49B | 4.98B | 69.59M | 525.67M | 0.5197 |
Pliant Therapeutics Inc Stock (PLRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-10-25 | Downgrade | JP Morgan | Neutral → Underweight |
| Mar-04-25 | Resumed | Cantor Fitzgerald | Neutral |
| Mar-04-25 | Downgrade | Needham | Buy → Hold |
| Mar-03-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Mar-03-25 | Downgrade | Stifel | Buy → Hold |
| Feb-10-25 | Downgrade | Canaccord Genuity | Buy → Hold |
| Feb-10-25 | Downgrade | Citigroup | Buy → Neutral |
| Feb-10-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Feb-10-25 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-10-25 | Downgrade | Oppenheimer | Outperform → Perform |
| Feb-10-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Feb-10-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Sep-09-24 | Resumed | Leerink Partners | Outperform |
| Dec-08-23 | Initiated | Wells Fargo | Overweight |
| May-18-23 | Initiated | Canaccord Genuity | Buy |
| Apr-13-23 | Initiated | Robert W. Baird | Outperform |
| Dec-14-22 | Initiated | Stifel | Buy |
| Dec-07-22 | Initiated | JP Morgan | Overweight |
| Sep-01-22 | Initiated | Citigroup | Buy |
| Jul-20-22 | Initiated | SVB Leerink | Outperform |
| May-25-22 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-21 | Initiated | Oppenheimer | Outperform |
| Nov-24-21 | Initiated | RBC Capital Mkts | Outperform |
| Nov-03-21 | Initiated | H.C. Wainwright | Buy |
| Apr-20-21 | Initiated | BTIG Research | Buy |
| Apr-05-21 | Initiated | Citigroup | Buy |
| Jun-29-20 | Initiated | Citigroup | Buy |
| Jun-29-20 | Initiated | Cowen | Outperform |
| Jun-29-20 | Initiated | Needham | Buy |
| Jun-29-20 | Initiated | Piper Sandler | Overweight |
View All
Pliant Therapeutics Inc Stock (PLRX) Latest News
What’s the beta of Pliant Therapeutics Inc. stockQuarterly Trade Report & Entry Point Confirmation Signals - mfd.ru
Pliant Therapeutics COO Kuo Minnie Sells $8853 in Shares By Investing.com - Investing.com India
Pliant Therapeutics CHRO Cheung sells $9.6k in stock By Investing.com - Investing.com Nigeria
Bernard Coulie Sells 89,375 Shares of Pliant Therapeutics (NASDAQ:PLRX) Stock - MarketBeat
Pliant Therapeutics COO Kuo Minnie Sells $8853 in Shares - Investing.com
Pliant therapeutics CFO Cummings sells $30,722 in stock By Investing.com - Investing.com Canada
Pliant therapeutics CEO Coulie sells $114k in shares By Investing.com - Investing.com Canada
Pliant therapeutics CEO Coulie sells $114k in shares - Investing.com
Aug Analyst Calls: Does Costamare Bulkers Holdings Limited stock reflect fundamentalsJobs Report & Verified Momentum Stock Alerts - baoquankhu1.vn
Analysis Recap: Is Pliant Therapeutics Inc benefiting from interest rate changesJuly 2025 WrapUp & Weekly High Momentum Picks - baoquankhu1.vn
Pliant Therapeutics Reports Improved Q3 2025 Results - MSN
Breakout Move: Whats the beta of Pliant Therapeutics Inc stock2025 Technical Patterns & AI Powered Market Entry Strategies - baoquankhu1.vn
Risk Check: What sentiment indicators say about Pliant Therapeutics Inc stockEarnings Risk Summary & Reliable Volume Spike Alerts - Bộ Nội Vụ
Pliant Therapeutics CFO sells $225,679 in stock - MSN
Is Pliant Therapeutics Inc. (9PT) stock prepared for digital transitionJuly 2025 Big Picture & Short-Term High Return Strategies - ulpravda.ru
Retail Trends: Is Pliant Therapeutics Inc. (9PT) stock worth holding before Fed meetingBreakout Watch & Safe Entry Zone Tips - Улправда
Can Pliant Therapeutics Inc. stock double in next 5 yearsStability vs Neutral Overview & HOKA model picks for your routine - Улправда
Will Pliant Therapeutics Inc. (9PT) stock beat revenue estimates2025 Biggest Moves & Daily Growth Stock Investment Tips - Улправда
Why retail investors pile into Pliant Therapeutics Inc. stockAnalyst Downgrade & Safe Swing Trade Setups - Улправда
Is Pliant Therapeutics Inc. (9PT) stock worth holding before Fed meetingBreakout Watch & Safe Entry Zone Tips - Улправда
How Pliant Therapeutics Inc. stock compares to market leadersBear Alert & Free Verified High Yield Trade Plans - Улправда
Aug Rallies: Can Pliant Therapeutics Inc. stock double in next 5 yearsJuly 2025 Chart Watch & Expert Approved Trade Ideas - Улправда
S P Trends: Can Pliant Therapeutics Inc. stock double in next 5 yearsJuly 2025 Intraday Action & Fast Moving Stock Watchlists - Улправда
Pliant Therapeutics, Inc. (NASDAQ:PLRX) Given Average Rating of "Reduce" by Analysts - MarketBeat
Pliant Therapeutics, Inc. (NASDAQ:PLRX) Given Average Rating of “Reduce” by Analysts - Defense World
NLC India Limited Breakout Confirmed by Volume MetricsResistance Breakout Alerts & Double Or Triple Profits - earlytimes.in
Weekly Earnings: What market sentiment indicators show for Pliant Therapeutics Inc 9PT stockWeekly Stock Analysis & Consistent Return Investment Signals - moha.gov.vn
What analysts say about Pliant Therapeutics Inc stockHigh Frequency Trading Trends & Free Triple Digit Wealth Increase - earlytimes.in
Pliant Therapeutics, Inc. (NASDAQ:PLRX) Short Interest Down 20.3% in December - MarketBeat
How Pliant Therapeutics Inc 9PT stock trades pre earnings2025 Buyback Activity & Daily Volume Surge Signals - moha.gov.vn
Pliant Therapeutics announces departure of chief medical officer - MSN
Pliant Therapeutics appoints Minnie Kuo as COO - MSN
Pliant Therapeutics, Inc.(NasdaqGS: PLRX) dropped from NASDAQ Biotechnology Index - marketscreener.com
Pliant Therapeutics appoints Minnie Kuo as chief operating officer By Investing.com - Investing.com Nigeria
Pliant Therapeutics appoints Minnie Kuo as chief operating officer - Investing.com
Pliant Therapeutics Appoints Minnie Kuo as COO - TipRanks
Pliant Therapeutics Appoints New Chief Operating Officer - TradingView — Track All Markets
Pliant Therapeutics (NASDAQ: PLRX) names Minnie Kuo Chief Operating Officer - Stock Titan
Pliant Therapeutics Earnings Notes - Trefis
Pliant Therapeutics, Inc. (NASDAQ:PLRX) Given Average Rating of “Reduce” by Brokerages - Defense World
Pliant Therapeutics, Inc. (NASDAQ:PLRX) Given Average Rating of "Reduce" by Brokerages - MarketBeat
Pliant Therapeutics, Inc. (PLRX) Presents at Piper Sandler 37th Annual Healthcare ConferenceSlideshow - Seeking Alpha
Pliant Therapeutics to end employment of chief medical officer Dr. Éric Lefebvre - Investing.com Nigeria
Pliant Therapeutics Announces Departure of Chief Medical Officer - TradingView
Pliant Therapeutics Inc Stock (PLRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.92%
2.36%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):